Rani Therapeutics Holdings, Inc.
Close on Oct 19, 2026
- Market cap
- $121.72M
- P/E (TTM)
- –
- Dividend yield
- –
Earnings
Next report expected Nov 5, 2026, during market hours (estimated from past report dates)
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q2 FY2026 Ended Jun 30, 2026 | Aug 13, 2026 | During market hours | $1.70M | – | – |
| Q1 FY2026 Ended Mar 31, 2026 | May 15, 2026 | During market hours | $1.70M | – | – |
| Q4 FY2025 Ended Dec 31, 2025 | Mar 26, 2026 | During market hours | $1.50M | $-0.07 | – |
| Q3 FY2025 Ended Sep 30, 2025 | Nov 6, 2025 | During market hours | – | $-0.12 | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 7, 2025 | During market hours | – | $-0.18 | – |
| Q1 FY2025 Ended Mar 31, 2025 | May 13, 2025 | During market hours | $200.00K | – | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 31, 2025 | During market hours | $1.00M | – | – |
| Q3 FY2024 Ended Sep 30, 2024 | Nov 14, 2024 | Before market open | – | $-0.24 | – |
| Q1 FY2024 Ended Mar 31, 2024 | May 6, 2024 | During market hours | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 20, 2024 | During market hours | – | – | – |
| Q3 FY2023 Ended Sep 30, 2023 | Nov 1, 2023 | During market hours | – | – | – |
Press releases
Announcements Rani Therapeutics filed with the SEC
Rani Therapeutics Reports Second Quarter 2026 Financial Results; Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Rani Therapeutics Reports First Quarter 2026 Financial Results; Provides Corporate Update; Announces CFO Transition
Results of operations · Listing notice · Executive or director change · EX-99.1 to Form 8-K
Rani Therapeutics Reports Fourth Quarter and Full Year 2025 Financial Results; Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Rani Therapeutics Reports Third Quarter 2025 Financial Results; Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Rani Therapeutics Reports Second Quarter 2025 Financial Results; Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Rani Therapeutics Reports First Quarter 2025 Financial Results; Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Rani Therapeutics Reports Fourth Quarter and Full Year 2024 Financial Results; Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Rani Therapeutics Reports Third Quarter 2024 Financial Results; Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Collaboration June 24, 2024 Exhibit 99.1
Material agreement · Other events · EX-99.1 to Form 8-K
Rani Therapeutics Reports First Quarter 2024 Financial Results; Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Rani Therapeutics Reports Fourth Quarter and Full Year 2023 Financial Results; Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Rani Therapeutics Announces Positive Topline Results from Phase 1 Study of
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
Our mission at Rani is to end painful injections for the millions of patients suffering from chronic diseases. Rani Therapeutics Corporate Presentation February 2024 NASDAQ: RANI
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rani Therapeutics Reports Third Quarter 2023 Financial Results; Provides Corporate Update
Results of operations · Executive or director change · EX-99.1 to Form 8-K
Rani Therapeutics Announces Strategic Program Prioritization, Expansion of Manufacturing and Plans to Streamline Business Operations to Support Near-Term Value Drivers and Long-Term Growth of the RaniPill ® Technology Platform; Reports Preliminary Third Quarter 2023 Financial Results
Material agreement · Results of operations · Exit or restructuring costs · EX-99.1 to Form 8-K
The RaniPill® Capsule, Rani Therapeutics’ Oral Delivery Platform, was Well-Tolerated in 60-Day, Repeat-Administration, GLP Safety Study
Other events · EX-99.1 to Form 8-K
Rani Therapeutics Announces Successful Drug Delivery of High-Capacity Pill in Preclinical Studies
Other events · EX-99.1 to Form 8-K
Rani Therapeutics Reports Second Quarter 2023 Financial Results; Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Rani Therapeutics Reports Fourth Quarter and Full Year 2022 Financial Results; Provides Corporate Update
Results of operations · EX-99 to Form 8-K
Rani Therapeutics Receives Feedback from Pre-IND Meeting with FDA; Provides Pipeline Update
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
Rani Therapeutics Announces Repeat-Dose Topline Results from RT-102 Phase 1 Study
Regulation FD disclosure · Other events · EX-99.1 to Form 8-K
RT-102 Phase I Study Part 2: Repeat-Dose Update December 2022
Regulation FD disclosure · Other events · EX-99.2 to Form 8-K
Rani Therapeutics Reports Third Quarter 2022 Financial Results and Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Rani Therapeutics Announces New RT-111 Development Program and
Other events · EX-99.1 to Form 8-K
Rani Therapeutics Reports Second Quarter 2022 Financial Results; Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Rani Therapeutics Reports First Quarter 2022 Financial
Results of operations · EX-99.1 to Form 8-K
Rani Therapeutics Reports Fourth Quarter and Full Year 2021 Financial Results; Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K
Oral Delivery of Biologics; Reports Preliminary 2021
Results of operations · Regulation FD disclosure · EX-99.1 to Form 8-K
RaniPill™ HC February 2022 Exhibit 99.2
Results of operations · Regulation FD disclosure · EX-99.2 to Form 8-K
Rani Therapeutics Reports Third Quarter 2021 Financial Results, Provides Corporate Update
Results of operations · EX-99.1 to Form 8-K